Integrated Care Boards (ICBs): What They Are and How Patients Can Contact Them

What is an ICB?

  • An Integrated Care Board (ICB) is the NHS organisation that replaced Clinical Commissioning Groups (CCGs) in July 2022.

  • Each ICB plans and funds NHS services across a large region (1–3 million people).

  • England has 42 ICBs, covering the whole country (see full list plus contact details here).

  • They hold the NHS budget locally, decide which services are provided, and work with councils and community organisations.

  • Scotland, Wales and Northern Ireland have a different system

Why might a patient need to contact an ICB?

Patients don’t normally deal with ICBs day-to-day (you’ll usually go to your GP, hospital, or local Patient Advice and Liaison Service). But there are situations where you may want or need to reach out:

  • Feedback or complaints about NHS services that can’t be resolved at GP or hospital level.

  • Service changes – ICBs must consult the public when they change how services are delivered (e.g. reorganising clinics, closing or merging hospital departments).

  • Patient voice – ICBs have teams dedicated to patient and public involvement. You can join forums, respond to surveys, or attend public meetings.

  • Access to care – if you are struggling to access a specialist service or want to know what’s available in your area, ICBs can advise.

  • Equality of access – raising concerns if a particular group or community is being left behind.

How can a patient contact an ICB?

  • Patient Experience / Engagement Teams: Every ICB has an email and phone number for patients. Look for “Get Involved” or “Contact Us” on their website.

  • PALS escalation: If PALS (Patient Advice and Liaison Service) can’t resolve your concern, they can refer it up to the ICB.

  • Public board meetings: ICBs must hold regular meetings in public where patients can submit questions.

  • Healthwatch: Your local Healthwatch can raise issues directly with the ICB on your behalf.

✅ In summary:
Patients usually don’t need to contact an ICB for routine issues, but if you want your voice heard about service changes, access problems, or unresolved complaints, the ICB is the organisation responsible for commissioning services in your area.

by GAtherton

Comparing Health Systems: NHS vs Insurance-Based Models

Healthcare looks very different depending on where you live, and it can be informative to look at the pros and cons of each system.
The UK’s NHS model is often contrasted with insurance-based systems such as those in the US and Germany. All aim to look after patients, but they differ in cost, access, caution with new medicines, and their contribution to research.

1. Funding and Access

NHS (UK)

  • Publicly funded through taxation.

  • Care is free at the point of use.

  • Limited co-payments (e.g. prescriptions in England, but free in Scotland/Wales/NI).

Insurance-Based (US, Germany)

  • US: Mix of private insurance, employer-based plans, and public programs (Medicare/Medicaid). Patients often pay premiums, deductibles, and co-pays.

  • Germany: Statutory health insurance (public) plus private options. Patients contribute through payroll and some co-payments.

✅ Equity difference: The NHS ensures universal coverage. Insurance systems can create gaps — in the US, uninsured or underinsured patients face very high bills.

2. Cost

  • United States: ~16–17% of GDP, >$12,000 per person per year.

  • Germany: ~11–12% of GDP, ~$6,000–7,000 per person.

  • United Kingdom: ~10% of GDP, ~$4,500 per person.

✅ Insurance-based systems are much more expensive overall. The NHS achieves lower cost per head but sometimes with tighter rationing.

3. Approach to New Medicines

NHS (cautious, evidence-driven)

  • Drugs are appraised by NICE (National Institute for Health and Care Excellence).

  • Only those proven clinically effective and cost-effective are routinely available.

  • Access can be slower, but ensures sustainability and safety.

Insurance-Based (faster, autonomy-driven)

  • Once a drug is licensed (FDA in US, EMA in EU), doctors may prescribe it, often off-label.

  • Patients may be offered newer or experimental options earlier.

  • Shared decision-making: “This might help, here are the risks, do you want to try it?”

✅ Trade-off: Insurance systems offer earlier access, but higher risk of side effects, wasted cost, and overuse. NHS offers more consistency but less flexibility.

4. Risks of Wide Access

Allowing rapid use of new drugs can lead to:

  • Harm to patients:

    • US:

      • Vioxx (rofecoxib) was widely prescribed for arthritis before long-term data was available → later linked to tens of thousands of excess heart attacks and strokes.

      • Opioid overprescribing (encouraged by drug companies, reimbursed by insurers) fuelled a public health crisis, with millions addicted and >500,000 deaths.

    • Germany: Wider acceptance of MCAS and other “working diagnoses” sometimes leads to long-term medication without solid evidence, exposing patients to risks without clear benefit.

  • Harm from NHS caution:

    • UK:

      • Cystic fibrosis drug Orkambi: available in the US and Germany years earlier, but withheld in the UK until 2019 due to cost-effectiveness debate → children and young adults missed out on years of treatment.

      • Cancer immunotherapies: delays in NICE approval have meant some patients only got access through special trials or not at all, potentially shortening survival.

5. Doctor–Patient Conversations

  • Insurance systems: “You may have this condition, and drug X or Y might help. It’s your choice.”

  • NHS: “We know you have this condition. X is proven and available. Y is unproven or not funded, so we cannot recommend it.”

✅ Insurance systems emphasise autonomy and options. The NHS emphasises evidence and fairness.

6. UK Private Healthcare vs US Healthcare

It’s tempting to think the UK private sector is equivalent to the US system, but they are very different.

UK Private Care

  • Covers about 10–12% of the population, mainly for elective surgery, scans, and faster consultant appointments.

  • Usually funded by employer insurance or self-pay.

  • Still relies on the NHS for emergencies and complex care.

  • New medicines still follow NICE approval — patients don’t usually get earlier access to unapproved drugs.

US Healthcare

  • Insurance-based and the default system, covering almost everyone.

  • Patients pay premiums, deductibles, and co-pays — bills can be catastrophic without good cover.

  • Emergencies are treated but still billed.

  • Patients may access new drugs and technology earlier, but often at very high cost.

✅ Bottom line: UK private care is an add-on to the NHS, giving faster access but within the same medical framework. The US system is entirely insurance-driven, with no NHS-style universal fallback.

7. Research Strengths

  • Insurance-based systems (esp. US):

    • Huge budgets (NIH + pharma).

    • Early adoption → more real-world data.

    • Specialist centres attract rare-disease patients.

  • NHS system:

    • Unified data across the whole population.

    • Ability to run massive pragmatic trials cheaply (e.g. RECOVERY during COVID: identified dexamethasone as life-saving within weeks).

    • More representative recruitment because care is universal.

✅ Together they complement each other:

  • New drugs are often developed and trialled first in the US/Germany.

  • Large-scale validation and population-level studies often happen in the UK.

8. Which System Is “Better”?

It depends what you value most:

  • Insurance-based systems:

    • More expensive

    • Faster access to innovation

    • More choice and autonomy

    • Higher risk of harm and inequality

  • NHS:

    • Less expensive

    • Slower, more cautious

    • Equitable and universal

    • Sometimes frustratingly restrictive

✅ Bottom Line

No system is perfect.

  • Insurance-based systems favour speed, choice, and innovation — but have caused harm through early adoption of unsafe drugs, opioid overuse, and inequitable access.

  • The NHS favours equity, safety, and sustainability — but has harmed patients by delaying access to life-saving treatments while cost-effectiveness was debated.

  • UK private healthcare is not a parallel US-style system: it is simply a faster lane within the NHS framework, not an alternative to universal coverage.

The reality is that both types of systems need each other: innovations often emerge in the US/Germany, while the NHS provides the gold standard for large-scale testing and equitable delivery.

by GAtherton

Mannose-Binding Lectin (MBL) Deficiency and Aspergillosis

What is MBL?

Mannose-binding lectin (MBL) is a natural protein made by the immune system. Its job is to help the body recognise and fight off germs, including fungi like Aspergillus. It’s part of the “innate” immune system – the first line of defence you’re born with.

How common is MBL deficiency?

MBL deficiency is surprisingly common.

  • Around 5–10% of people have very low or absent levels.

  • If you include milder reductions, as many as 20–30% of people carry genetic changes that lower MBL activity.

For most, this causes no problems because the immune system has other pathways to fall back on. People often never know they have it.

Why do MBL levels vary?

  • Genetics: The MBL2 gene comes in different versions, some producing plenty of MBL and others producing little or none.

  • Inheritance: The combination of gene copies from each parent determines your level.

  • Normal diversity: Low levels are common and often harmless, showing the immune system has strong backup pathways.

Are some people born more vulnerable to infection?

Yes – but it depends on the situation.

  • Children with very low MBL may get more ear, chest, or sinus infections while their immune systems are developing.

  • In adults, MBL deficiency usually only matters if there are other risks, such as chronic lung disease, immune suppression, or another immune problem.

  • Many people with low MBL live their whole lives without extra infections.

MBL deficiency and aspergillosis

On its own, MBL deficiency rarely causes illness. But in people who already have other risks – such as lung disease (COPD, asthma, bronchiectasis, or TB damage) or a weakened immune system – it may make infections more likely.

Research suggests MBL deficiency can be linked to:

  • Chronic pulmonary aspergillosis (CPA)

  • Allergic bronchopulmonary aspergillosis (ABPA)

  • Invasive aspergillosis in people with suppressed immunity

In these cases, MBL deficiency is not the single cause of aspergillosis, but it may be one of several factors that increase vulnerability.

Can MBL deficiency be treated?

At present, there is no routine treatment to replace MBL itself. Research has explored giving purified MBL, but it hasn’t become a standard therapy – largely because deficiency is so common and most people remain healthy without intervention.

Instead, management focuses on:

  • Treating infections promptly with antibiotics or antifungals

  • Sometimes using preventive (prophylactic) antibiotics or antifungals in people with frequent or severe infections

  • Using immunoglobulin replacement therapy if there are additional immune problems

  • Supporting lung health and reducing risks with vaccinations, good self-care, and specialist monitoring

Why measure MBL if it can’t be treated directly?

Even without a direct treatment, measuring MBL can still be useful:

  1. Helps explain recurrent infections – finding a low MBL level can give part of the reason why someone is more prone to infections.

  2. Part of a bigger immune work-up – it’s often checked alongside other immune tests, and the overall pattern may guide treatment decisions.

  3. Risk awareness – knowing about low MBL can make doctors more proactive with antibiotics, antifungals, or vaccinations, and encourage earlier treatment at the first sign of infection.

  4. Research value – helps specialists understand why some people develop aspergillosis while others don’t.

Why hasn’t evolution eliminated low MBL?

  • Common worldwide: 5–10% of people have very little MBL, and up to 30% have reduced levels. If this were a major disadvantage, numbers would be lower.

  • Other immune pathways compensate: The body has strong backup systems, so many people stay healthy even with low MBL.

  • Possible advantage: In some infections, high MBL may drive too much inflammation. Lower MBL might have protected against diseases like leprosy or TB.

  • Changing disease patterns: In the past, people rarely lived long enough for chronic lung disease to show the effects of low MBL. Today, with longer lives and modern medicine, its role is more visible.

👉 In short: low MBL has not been “selected out” by evolution because it usually isn’t harmful on its own, and in some situations it may even have been protective.

What this means for patients

  • Having MBL deficiency is quite common and usually harmless.

  • It may become more relevant if you also have underlying lung disease or are on treatments that suppress the immune system.

  • If MBL deficiency is suspected, doctors may check for it as part of a wider immune work-up.

  • The key point: treatment is aimed at managing infections and lung health, not the MBL level itself.

👉 In short: MBL deficiency is common in the general population. Most people never notice it, but for some with lung disease or weakened immunity, it may add to the risk of aspergillosis. While there’s no direct treatment for the deficiency, testing can help explain recurrent infections, guide wider immune checks, and shape preventive care.

by GAtherton

Autumn 2025 COVID-19 Booster – What Aspergillosis Patients Need to Know

The UK Health Security Agency (UKHSA) has updated who will be offered the COVID-19 booster this autumn. The programme is now more limited than in 2024, so it’s important to know if you qualify.

Who will be offered the booster?

You can get a free COVID-19 booster this autumn if you are:

  • Aged 75 or over

  • Living in a care home for older adults

  • Aged 6 months or older and immunosuppressed

This is a change from 2024, when everyone aged 65+ and many other clinical risk groups were included.

What “immunosuppressed” means

Many people with aspergillosis fall into this category. You may be considered immunosuppressed if you are:

  • Taking systemic steroids for more than a month

  • Receiving biologic therapy or other immunomodulatory medication

  • Living with a condition that affects your immune system

  • Having had chemotherapy, radiotherapy, or a transplant

If you’re unsure whether this applies to you, check with your GP or hospital specialist.

Timing of the booster

  • Boosters are usually offered at least 6 months after your last dose, including the spring booster.

  • Even if you’ve never had a COVID-19 vaccine before, you can still get one this autumn if you are in one of the eligible groups.

Why this matters for aspergillosis patients

People with aspergillosis often have weaker lungs and higher risks from infections. If your immune system is also suppressed by medication or illness, COVID-19 can be more severe. The booster offers added protection during the winter months.

💙 Key advice:

  • If you are immunosuppressed or over 75, you should be offered the vaccine.

  • If you think you qualify but haven’t received an invitation, speak to your GP or specialist.

  • Don’t delay — protecting yourself against COVID-19 is especially important when living with aspergillosis.

📌 Full details from UKHSA: Who’s eligible for the 2025 COVID-19 vaccine or autumn booster

by GAtherton

Drug Safety in the UK: What Aspergillosis Patients Need to Know

Living with aspergillosis often means taking powerful medicines for a long time — antifungals, steroids, antibiotics, or even biologics. These treatments can be life-saving, but they can also cause side effects, especially when used together. It’s natural to wonder: How do we know these drugs are safe? What happens if something goes wrong?

This article explains how drug safety is managed in the UK, what happens when rare problems occur, and what resources patients can use to protect themselves.

How Medicine Safety Works

Before a drug is approved:
Every new medicine goes through several phases of clinical trials. These trials are not just about proving that the drug works (efficacy) — they are also about proving it is safe enough to use in people. Researchers record every possible side effect, monitor blood tests, and look for safety signals as well as improvements in the illness.

However, trials have limits. They usually include only a few thousand participants, so they can reliably detect common side effects but not very rare ones. For example, if a side effect happens in 1 in 100,000 people, and a trial only studies 50,000, it may not appear at all.

After a drug is approved:
Once a medicine is prescribed to thousands or millions of people, those rare side effects start to appear. For example, in the first million patients, perhaps 10 cases may be reported. That’s not manipulation — it’s just the maths of large numbers.

How Do Doctors Link a Side Effect to a Medicine?

When someone develops a new symptom, it isn’t always obvious whether it’s caused by their illness, another condition, or the medicine they’re taking. Linking a side effect to a drug usually involves several steps:

  1. Timing – Did the symptom start soon after beginning the medicine? Did it improve when the medicine was stopped? Timing is often the strongest clue.

  2. Known side effect profile – Doctors check if the symptom has been reported before in trials, studies, or drug safety updates.

  3. Other explanations – Could it be the underlying condition (like aspergillosis) or another drug? All possible causes are reviewed.

  4. Drug interactions – Many side effects come from the way medicines interact, rather than one drug alone. Antifungals like itraconazole and voriconazole interact with steroids, antibiotics, and heart drugs.

  5. Rechallenge (rarely used) – Sometimes a drug is restarted to see if the side effect returns. This can provide strong evidence but is only done when absolutely necessary.

  6. Patient reporting – A single case may not prove much, but when dozens of patients report the same issue, patterns become clear.

🔎 Key message: It’s not always quick or simple to prove a side effect. That’s why your own observations — when it started, how it feels, what other medicines you’re on — are so valuable to your doctors and to the Yellow Card system.

What Happens to Those Patients?

  • Every case is recorded and investigated. Regulators like the MHRA (Medicines and Healthcare products Regulatory Agency) look for patterns.

  • If a link is confirmed, they can issue warnings, add monitoring requirements, restrict use, or withdraw the drug.

  • For the patients affected, the drug is usually stopped, and supportive treatment is given. Sadly, in some cases, harm cannot be reversed.

This is why reporting side effects is so important. Each individual case helps build the full safety picture and protects others in the future.

Is This “Experimenting on Patients”?

It can sometimes feel that way — because new medicines are still watched closely after approval, and some harms are only seen later.

But there’s an important distinction:

  • Clinical trials are the experiments, and they are about safety as much as efficacy. Every trial phase collects safety data, and a medicine cannot be approved unless it is shown to be safe enough for use.

  • Post-marketing monitoring is not an experiment — it’s a safety net that exists for all medicines, because no trial is ever large enough to catch every very rare problem.

Patients aren’t being experimented on after approval, but your experience does matter. Every report adds to knowledge and helps keep medicines safe for everyone.

Who Is Liable If Harm Occurs?

  • Negligence (e.g. wrong dose, ignoring abnormal tests): the prescriber or hospital may be liable.

  • Defective product or hidden data: the manufacturer may be held responsible, sometimes through compensation schemes or legal action.

  • Very rare, unpredictable events despite correct use: liability is often less clear, and compensation is not guaranteed.

This can feel unfair. A few patients may suffer harm without anyone being “at fault.” That’s why strong safety monitoring and reporting are so essential.

Balancing Benefit and Risk

If 10 people out of a million are harmed, 999,990 people may have been helped — often in life-saving ways. That doesn’t make the harm any less real, but it explains why regulators still approve medicines with very rare risks: the benefit to the vast majority outweighs the small chance of harm, as long as those harms are recognised and acted on quickly.

Looking forward, science may allow us to predict who is at risk of those 1-in-a-million harms (through genetics or biomarkers) and screen them out — so that only those who can benefit safely receive the drug.

Key UK Drug Safety Resources

Here are the most useful resources for patients in the UK:

What Aspergillosis Patients Need to Remember

Because aspergillosis often requires long-term, powerful medicines like itraconazole, voriconazole, posaconazole, steroids, or biologics, patients are more likely to:

  • Experience side effects

  • Need regular blood tests to check drug levels

  • Take multiple medicines with possible interactions

Three key takeaways:

  1. Know where to look – check NHS Medicines A–Z or your medicine leaflet (eMC) if you’re unsure about a side effect.

  2. Report problems – use the Yellow Card scheme to flag any suspected reaction.

  3. Stay in touch with your team – never stop or change your medicine without advice, but do share new symptoms with your GP or specialist promptly.

✅ Bottom line: Clinical trials test both safety and effectiveness, but no study can capture every rare event. That’s why medicines continue to be monitored after approval, and why patient reporting is so important. By working together — patients, doctors, and regulators — we make medicines safer for everyone.

by GAtherton

Side Effects, New Medicines, and Safety Reporting: What Every Patient Should Know

Modern medicines, including antifungals used for aspergillosis, can be life-saving. But they can also have powerful side effects. One patient recently described developing nerve damage (neuropathy) while on treatment, but never mentioned it to their doctor, because they didn’t know it could be a side effect. Sadly, by the time it was recognised, the damage was permanent.

This story shows why patients and doctors need to work together in partnership to spot and report side effects early — especially when medicines are new and real-world safety data is still limited.

1. From passive role to partnership

In the past, healthcare was one-way: the doctor gave instructions, the patient followed. Today the NHS encourages shared responsibility:

  • Doctors bring their expertise about the illness and treatments.

  • Patients bring their daily experience of living with the condition.

  • Together they can make safer, better-informed decisions.

This partnership is essential for powerful drugs like antifungals, where side effect monitoring depends on both sides working together.

2. Why side effect statistics can be misleading

Leaflets list side effects as “common” or “rare,” often with percentages. But these figures don’t always reflect real life because:

  • Trials are limited – only a few thousand people take part, often younger and healthier than typical NHS patients.

  • Under-reporting is common – doctors and patients often fail to report side effects, especially mild ones.

  • Bias exists – severe or unusual reactions are reported more often than everyday ones.

👉 Bottom line: leaflets tell us what can happen, not always how often it happens.

3. The Yellow Card system

The UK’s main tool for detecting safety issues is the Yellow Card Scheme, run by the MHRA.

  • Anyone can report: doctors, nurses, pharmacists, patients, or carers.

  • Reports are vital: patterns in these reports may reveal risks not seen in trials.

  • Action is taken: if needed, leaflets are updated, warnings issued, or drugs restricted/withdrawn.

You can report suspected side effects at yellowcard.mhra.gov.uk.

4. Why reporting matters

Poor reporting leads to harm:

  • Delayed warnings – e.g. photosensitivity with voriconazole took years to be recognised.

  • Biased safety data – drugs may seem safer than they are.

  • Preventable harm – patients may suffer permanent injury before action is taken.

For new medicines (marked with a ▼ black triangle in the BNF and leaflets), the MHRA asks for all side effects to be reported, no matter how small.

5. Extra protections for new medicines

When a drug is new, safety systems are stronger than usual:

  • Black triangle (▼) – signals “additional monitoring” so all suspected ADRs should be reported.

  • Specialist prescribing – new antifungals are usually limited to centres like NAC.

  • Closer monitoring – frequent blood tests, drug levels, eye or skin checks depending on risk.

  • Risk Management Plans – agreed with regulators, spelling out what to watch for.

  • Post-marketing studies – Phase 4 trials track safety in real-world patients.

These safeguards are extensive, but not fool-proof. Rare or long-term effects may still emerge only after years of wider use.

6. The NHS challenge

Despite the systems:

  • Only a small percentage of doctors file Yellow Card reports each year.

  • Most GPs never prescribe brand-new drugs — so reporting falls heavily on specialist centres like NAC.

  • Under-reporting risks harm, increases NHS costs, and erodes trust.

7. Who sets the rules?

Several organisations provide guidance on reporting and safety:

  • MHRA (UK regulator): runs Yellow Card, monitors new and established drugs, and issues safety updates.

  • BNF (British National Formulary): highlights side effects, black triangle drugs, and links to reporting tools.

  • GMC (General Medical Council): obliges doctors to report serious ADRs and all reactions to ▼ drugs.

  • EMA (European Medicines Agency): operates EudraVigilance, pooling reports from across Europe.

  • Global standards: the UK follows international rules (ICH E2B) so data is shared worldwide.

8. What patients can do

You are central to this safety net:

  • Be observant – notice anything new or unusual.

  • Keep a record – note when it started, how often, and any changes with medication.

  • Report promptly – tell your team and consider submitting a Yellow Card yourself.

  • Ask questions – “What side effects should I look out for? Which are urgent? How will we monitor this drug?”

  • Use trusted sources – NHS.uk, bnf.nice.org.uk, NAC, or your pharmacist.

9. The reality of side effects

For many, side effects are not “minor inconveniences.” They can mean:

  • Permanent disability (e.g. nerve or vision damage).

  • Loss of independence or mobility.

  • Social isolation and depression.

That’s why side effect monitoring is not just bureaucracy — it’s about protecting real lives.

Key message

The systems around new medicines are extensive but not fool-proof. That’s why patients and doctors must work as partners.

👉 If you notice something new, strange, or worrying while on antifungal medication — however small — tell your healthcare team and consider reporting it. Your report may be the missing piece that protects you and others.

by GAtherton

Working With Your Medical Team: What Every Patient With Aspergillosis Needs to Know

Modern antifungal treatments, and many of the medicines used alongside them, can be life-saving. They help control infections that would otherwise cause severe damage to the lungs and other organs. But these medicines are also powerful, and like all strong treatments, they sometimes carry risks.

One patient recently shared that they developed nerve damage (neuropathy) while taking antifungal medication, but did not mention it to their doctor because they did not know it could be a side effect. Sadly, problems like this can sometimes become permanent if not spotted early.

This raises an important question: what do patients need to know about their responsibilities when taking medicines like antifungals, and more broadly, when living with aspergillosis?

From passive role to partnership

In the past, healthcare often worked in one direction: the doctor gave instructions, and the patient was expected to follow them. Patients were mostly passive, with little chance to ask questions or take part in decisions.

The NHS is now moving towards a very different way of working: partnership.

This means:

  • Doctors and nurses share their medical knowledge.

  • Patients share their experiences of living with their condition.

  • Together, both sides decide what treatment and care will work best.

Why doctors sometimes hesitate about side effects

Some patients are surprised to learn that not all doctors automatically tell patients about possible side effects. Why is this?

  • Some worry about causing anxiety or putting patients off treatment.

  • Others fear the nocebo effect — where simply knowing about a side effect can make someone more likely to notice it.

  • They may also feel that handing over a long list of possible effects is overwhelming.

But when it comes to antifungals and other long-term, powerful medicines, not knowing can be dangerous. If patients do not know what to look for, they may ignore early signs of serious problems until it is too late.

The best approach is balance:

  • Patients don’t need to memorise an endless list.

  • They do need a clear, short list of the most important and urgent symptoms to look out for — and to know what to do if they appear.

Medicines: what patients should do

  • Take medicines as prescribed – antifungals, inhalers, steroids, or biologics must be taken on schedule. Missing doses can reduce effectiveness or drive resistance.

  • Do not stop suddenly – especially steroids. Always follow tapering advice.

  • Check for interactions – antifungals can clash with common medicines such as statins, blood pressure tablets, and painkillers. Always tell your team about new prescriptions, over-the-counter drugs, or supplements.

  • Use the same pharmacy if possible – so interactions are checked consistently.

Monitoring your health

  • Attend all scheduled tests – blood work, lung function, CT scans. These can reveal hidden changes before you feel them.

  • Know your “normal” – keep track of oxygen levels (if you use a pulse oximeter), peak flow, sputum colour, cough, and breathlessness.

  • Spot infections early – worsening cough, fever, or new sputum colour may mean infection or flare-up. Report these quickly.

Communication with your team

  • Bring notes to clinic – write down questions and symptoms so nothing is forgotten.

  • Be open and honest – if you’ve missed doses, struggled with side effects, or found treatment difficult, let your team know.

  • Keep contact details handy – know who to call if problems arise (specialist nurse, hospital helpline, GP).

Lifestyle and prevention

  • Reduce exposure to moulds – avoid compost heaps, rotting leaves, damp basements, and building dust. If you cannot avoid them, wear an FFP2/3 mask.

  • Protect your lungs – keep up with vaccinations (flu, COVID-19, pneumococcal).

  • Support your overall health – eat well, stay as active as you can, and rest when needed.

  • Look after your mental health – chronic illness is stressful. Patient groups, counselling, or peer support can make a big difference.

Self-management skills

  • Recognise flare-ups – learn the difference between ABPA flare, CPA progression, and bacterial infection symptoms.

  • Know your rescue plan – what to do if you suddenly worsen (extra inhalers, antibiotics, or emergency help).

  • Keep records – note symptoms, hospital visits, and medication changes. This helps spot long-term patterns.

  • Be part of decisions – ask about benefits, risks, and alternatives of treatments. Care should fit your life as well as your lungs.

Where to find reliable information on medicines

Many patients say the leaflet in the medicine box is written in tiny print or feels overwhelming. You do have other options:

  • Ask your clinical team or pharmacist — they can give you a short list of the most important side effects to watch for and explain what’s urgent.

  • Check the BNF (British National Formulary) online — the NHS makes this trusted reference free to the public at bnf.nice.org.uk. It lists side effects, drug:drug interactions, and safety notes.

  • Use NHS.uk — clear pages on most medicines, written in plain English.

  • Patient support organisations — such as the National Aspergillosis Centre or relevant charities, which often provide tailored advice.

If you’re unsure, it’s always safer to ask rather than guess.

The bigger picture: partnership

In the past, doctors made decisions and patients followed instructions. Today, with complex conditions like aspergillosis, patients are central members of the care team.

  • You notice problems first.

  • You take daily responsibility for medication.

  • You decide when to seek help.

This isn’t about shifting the whole burden onto patients — it’s about recognising that care works best when it is a true partnership.

Key message

👉 If you notice something new, strange, or worrying while on antifungal medication — however small — tell your healthcare team. Don’t assume it’s not important.

And remember: safe, effective treatment is a two-way street. Your role as a patient is not just to take medicines, but to observe, record, communicate, and partner with your team. That partnership is what keeps you safe and makes your treatment work.

by GAtherton

Misinformation on Social Media: Health and Beyond

Social media helps us stay connected, share experiences, and find support. But it also spreads false or misleading stories — about health, politics, money, and world events. These stories can cause unnecessary fear, confusion, and sometimes real harm if people act on them.

Understanding why misinformation spreads, what’s being done about it, and how to spot it helps keep you and your loved ones safe.

🚩 Why do false stories spread?

  1. Algorithms reward attention
    Platforms are designed to keep you scrolling. Content that shocks (“miracle cure discovered!”), scares (“hidden danger you’re not being told about!”), or excites spreads the fastest — even if it isn’t true.

  2. Anyone can post anything
    Unlike newspapers, medical journals, or BBC/NHS websites, most social media posts aren’t checked by editors or experts before going live.

  3. Echo chambers
    Platforms show you more of what you already click on. If you read about miracle diets or political conspiracies, you’ll see more of them — true or not.

  4. Deliberate misinformation
    Some people spread falsehoods deliberately:

    • To sell fake health products

    • To make money from clicks

    • To influence politics or sow division

  5. Speed beats accuracy
    False stories can go viral in minutes. Corrections are slower and rarely reach as many people.

⚖️ What’s being done about it?

Legal approaches

  • UK: The Online Safety Act (2023) requires platforms to remove illegal or harmful misinformation, including dangerous health advice.

  • EU: The Digital Services Act (DSA) makes large platforms responsible for acting faster against harmful content.

  • Extreme cases: Fraud, scams, defamation, or incitement of violence are not protected speech and can be prosecuted.

Technical approaches

  • Algorithms: AI flags suspicious posts.

  • Labelling: Content can be marked as “false” or “missing context.”

  • Bot control: Platforms limit fake accounts that spread stories at scale.

  • Digital nudges: Some apps ask “Do you want to read before sharing?” or warn if a post is outdated.

The limits

  • Freedom of speech protects many misleading opinions unless they cause direct harm.

  • Global reach makes it hard to police.

  • Volume — billions of posts daily are impossible to check one by one.

  • Trust — some people ignore fact-check labels, believing platforms are biased.

🧐 How to know what’s real

Five quick checks:

  1. Who is posting it? NHS, WHO, BBC, or Reuters → reliable. Unknown influencer or “miracle cure” shop → beware.

  2. Is it reported elsewhere? Real news appears in multiple reputable outlets.

  3. Does it use scare tactics or hype? “Doctors don’t want you to know this secret cure!” → red flag.

  4. Can you fact-check it? Try NHS.uk, Full Fact (UK), Snopes, Reuters Fact Check or BBC Verify.

  5. Check dates and pictures — old or unrelated content is often recycled to look new.

🚦 The traffic-light test

  • 🟢 Green – from official sources, confirmed, calm tone → likely true.

  • 🟡 Amber – source unclear, dramatic style, no confirmation elsewhere → pause, check.

  • 🔴 Red – sensational, “miracle” claims, conspiracy, or urging you to share → almost certainly false.

💡 Should we avoid social media completely?

Not necessarily. Social media has real value for support, awareness, and connection. The key is using it wisely:

  • Follow trusted organisations for health and news.

  • Unfollow or mute accounts that regularly spread falsehoods.

  • Balance social media with direct trusted sources (NHS, GP, recognised news).

  • Step away if scrolling leaves you anxious, angry, or confused.

✨ Bottom line

False stories spread online because the system rewards attention, not accuracy. Laws and technology help, but they can’t stop misinformation entirely.

The best defence is awareness. Before acting on or sharing any post — whether about health, politics, or world events — pause, check, and if in doubt, don’t share.

👉 Protecting yourself from misinformation means protecting your community too.

by GAtherton

📚 New Children’s Book Helps Families Understand Aspergillosis

Launch Event at Affinity Outlet, Fleetwood – 13th September 2025

The Aspergillosis Trust is delighted to announce the launch of a brand-new children’s book, Dad and the Sneaky Spores, written by award-winning author Christina Gabbitas and beautifully illustrated by Ursula Hurst.

This story has been specially commissioned to raise awareness of aspergillosis, a serious lung condition caused by the Aspergillus fungus. Through gentle storytelling and colourful illustrations, the book helps children and families understand what it means to live with a parent affected by aspergillosis.

✨ About the Event

📅 Date: Saturday 13th September 2025
📍 Location: Affinity Outlet, Fleetwood

The launch event will be a fun and informative day for all the family.

  • ✍️ Meet the Author: Christina Gabbitas will be signing copies of the book between 12pm and 2pm.

  • 👩‍⚕️ Ask the Experts: A qualified nurse will be available to answer medical questions or offer advice.

  • 📚 Learn Together: Families can explore how storytelling can make complex health conditions easier to understand.

📖 About Dad and the Sneaky Spores

The book follows a family’s journey with aspergillosis in a way that children can relate to. It not only explains the illness but also encourages empathy, resilience, and understanding within families.

“The narrative not only educates readers about aspergillosis but is also thoughtfully crafted to foster empathy and understanding.” – Aspergillosis Trust

Published by Poems & Pictures, Dad and the Sneaky Spores is available from 1st August 2025.

💜 Why This Matters

Aspergillosis is a rare and often misunderstood condition. By raising awareness through creative storytelling, this initiative provides a new way to start important conversations with children, families, and the wider community.

🔗 Find out more at: www.aspergillosistrust.org

by GAtherton

NHS England - You and Your GP: Key Points for NHS Patients Managing Aspergillosis

You and your general practice (YYGP) has been developed to help patients understand what to expect from their general practice and how they can get the best from their GP team. YYGP also enables patient to provide feedback or raise concerns with their GP Practice, Healthwatch or the integrated care board. The contract requires every GP practice to have linked to the NHS England YYGP document on their website, no later than 1 October 2025.

1. Accessing Your GP

  • Opening hours: Your GP is typically open 8:00 – 18:30, Monday to Friday. You can walk in, call, or use the NHS App or practice website to contact them NHS England.

  • If closed: For urgent but non-emergency needs, use 111 online or by calling 111 NHS England.

  • In an emergency: If symptoms are life-threatening (e.g., sudden severe breathing issues), go to A&E or call 999 NHS England.

2. Making an Appointment

  • When you contact your GP—whether by phone, online, or in person—they’ll assess your condition and respond within one working day with next steps NHS England.

  • This could include:

    • A face-to-face appointment

    • A phone consultation

    • A text message with advice

    • A recommendation to consult a pharmacy or another NHS service NHS England.

This prompt response is especially important for aspergillosis fluctuations or side effects from antifungal treatments.

3. Who You'll See

  • You may be seen by a GP, nurse, or pharmacist.

  • If you have a designated carer, they can speak on your behalf (with your permission).

  • If you prefer a specific healthcare professional you trust, request them—though waits might be longer NHS England.

  • Seeing the same clinician regularly can be beneficial for managing complex, long-term conditions like aspergillosis NHS England.

4. Support for Additional Needs

  • If English isn't your first language, you can request interpretation services when booking an appointment.

  • If you need extra help—like longer appointments, a quiet space, wheelchair access, or materials in accessible formats—just let the practice know; they'll try to accommodate NHS England.

5. Changing or Selecting a GP

  • You can find or switch to a GP using the NHS website (“Find a GP”) or by contacting local practices directly NHS England.

  • No ID, NHS number, or proof of address is needed to register—even if you’re homeless or your immigration status is uncertain NHS England.

  • If a practice cannot register you, they must explain their decision in writing within 14 days NHS England.

6. Referral and Treatment Flexibility

  • If your GP refers you to a specialist (e.g., respiratory consultant), you often have the right to choose your hospital or clinic NHS England.

7. Free Care & Private Work

  • GP services are free, including appointments and treatments.

  • Extra services like insurance letters may incur a fee NHS England.

8. Being a Helpful Patient

  • Prepare for appointments: list symptoms, treatment concerns, and questions in advance.

  • Be punctual or cancel in good time to avoid delays for others.

  • Use the NHS App or website to book appointments, refill prescriptions, and view test results.

  • Turn on App notifications to stay updated with messages from your practice NHS England.

  • Order repeat prescriptions well ahead—especially vital when managing antifungal medications—to avoid running out NHS England.

  • Consider joining the Patient Participation Group at your practice to share feedback and help improve services NHS England.

9. Sharing Feedback or Concerns

  • To raise concerns, talk to your practice manager first.

  • If needed, you can escalate feedback to your local Integrated Care Board (ICB).

  • You can also reach out to your local Healthwatch (an independent NHS watchdog) for confidential advice and support NHS England.

Why This Matters for Aspergillosis Patients

Aspergillosis often requires ongoing monitoring, regular breathing tests, imaging, and antifungal therapy adjustments. Timely access to GP services, continuity of care, and preparedness all enhance your ability to manage flare-ups or side effects effectively.

Handy Checklist (for easy reference)

Task
Contact GP promptly for new or worsening symptoms
Prepare questions ahead—e.g., changes in breathing, treatment effects
Use NHS App to manage appointments and medications
Order repeat prescriptions early to maintain drug access
Request support services if needed (interpretation, accessibility)
Provide feedback to improve your experience and others'

by GAtherton